The Asymmetrical Shield: How Section 6(b) Changes Your Defense Strategy

The American Law Institute rewrote the rules for medical malpractice — and buried inside the 2024 Restatement is a provision most physicians have never heard of. Section 6(b) creates a one-directional shield: evidence-based practice can defend you, but plaintiffs cannot use it against you. This episode breaks down the three defense pipelines it opens, what it means for documentation, and why the physicians who understand this shift will be better protected than those who don't.

Transcript

SPEAKER_03 0:44

It is 2 14 a.m. You are the overnight hospitalist covering a 28-bed service. The emergency physician calls with an admission. A 54-year-old man with substernal chest pain. Troponin negative times two. Heart score of three. Low risk. The ED wants to admit for observation and serial troponins. You push back. The heart pathway literature is clear. A score of three or below with two negative high-sensitivity troponins identifies patients at less than 1% risk of major adverse cardiac events at 30 days. The evidence supports discharge without patient follow-up. Not an inpatient admission that exposes the patient to hospital acquired risk and the system to unnecessary cost. You discharge the patient. You document your reasoning. Heart score, serial troponins, risk stratification, shared decision making, return precautions. Six weeks later, the patient has a myocardial infarction. The family sues.

SPEAKER_02 2:03

Under the old legal framework, the central question would have been simple. What do most hospitalists do with a heart score of three? And if the customary practice in your region was to admit and observe, you lose, even though the evidence was on your side.

SPEAKER_03 2:18

Under the 2024 restatement of the law, third torts medical malpractice, the question shifts. And a provision most physicians have never heard of, Section 6B, may hand you the strongest defense tool in modern malpractice law. This is the Charted Defense. I am Brian.

SPEAKER_00 2:43

I am Sarah.

SPEAKER_02 2:44

And I am Michael Coleman. Today we are going deep on a single provision of the 2024 restatement, Section 6B, the asymmetrical shield, how it works, why it only runs in one direction, and the three defense pipelines it creates for every physician who documents their clinical reasoning.

SPEAKER_03 3:03

Before we go further, what this episode covers and what it does not. If you have not read or listened to that piece, start there. It provides the foundational context for everything that follows today. This episode narrows to a single provision, Section 6B, and its strategic implications for your defense if you are ever sued.

SPEAKER_00 3:53

A few critical framing points. The restatement is persuasive authority. It does not automatically become law in any state. No court has applied Section 6B as binding precedent. The defense pipelines we describe today are analytical constructs, logical applications of Section 6, B, combined with existing procedural mechanisms like summary judgment and Daubear motions. They represent what is strategically available under the restatements framework, not what has been tested in court. That said, the gravitational pull is real. The Texas Supreme Court cited Section 5, A, in a 2024 opinion, and Section 15 in 2025. The United States Supreme Court cited Section 11 in March 2026. Courts are paying attention. And the Defense Bar is already studying how to operationalize Section 6, B.

SPEAKER_02 4:53

Our discussion today draws on the restatements approved sections, the ALI's official commentary, the 2025 JAMA synthesis by Aaron, Robertson, King, and Sage, the critique by Stuart and Peck in the American Journal of Law and Medicine, they called it a bridge too far, Hall's published response defending the provision, and recent Alabama Supreme Court decisions, including ex parte Stephen M. Taylor, M.D. and Hickson versus Premier Medical Group, both from 2025.

SPEAKER_03 5:24

Section 6 of the restatement addresses how breach of the standard of care is established. Most of the attention since May 2024 has focused on Section 5, the shift from custom to competence. But Section 6B may prove more consequential in the courtroom. Sarah, walk us through what it actually does.

SPEAKER_00 5:49

Section 6B creates what I would describe as an asymmetrical evidentiary rule, and it is the most debated provision in the entire restatement. Here is how it works. For defendants, compliance with an authoritative clinical practice guideline can serve as prima fasci evidence of non-breach. If a physician followed a guideline that is methodologically rigorous, evidence-based, and issued by a recognized medical body, that compliance alone can support a finding that the care was competent. Even without additional expert testimony on that specific point. For plaintiffs, noncompliance with a guideline does not receive the same treatment. A plaintiff cannot point to a guideline the physician did not follow and use that noncompliance as standalone prima fasci evidence of breach. They can introduce guideline noncompliance as evidence, but it must be established through the traditional mechanism. Qualified expert testimony explaining why the deviation fell below the competence standard.

SPEAKER_03 6:51

So defendants get a procedural shortcut. Plaintiffs do not.

SPEAKER_00 6:55

That is exactly the criticism. Stuart and Peck, writing in the American Journal of Law and Medicine, called this provision novel and unprecedented. They argue it creates an unfair procedural advantage for defendants and potentially conflicts with existing evidentiary rules governing the admissibility of guidelines in court.

SPEAKER_02 7:16

Let me put that in clinical terms. If I follow the heart pathway protocol, document it, and the patient has a bad outcome, under Section 6B, my attorney can present that guideline compliance as standalone evidence that my care met the standard. That is a powerful starting point. But if a physician ignores, say, the ACCP guidelines on anticoagulation for pulmonary embolism, the plaintiff's attorney cannot just point to those guidelines and say, he did not follow this, therefore he breached the standard. They still need an expert witness to build that case through traditional testimony.

SPEAKER_03 7:53

Hall, one of the REST statements reporters, defended the asymmetry. What was his argument?

SPEAKER_00 8:00

Hall's position is that authoritative guidelines represent the collective judgment of the medical profession, distilled through rigorous methodology, allowing them to serve as prima faccia defensive evidence, reduces the noise of partisan expert battles, and aligns malpractice law with evidence-based medicine. The asymmetry, he argues, is intentional. Guideline compliance is a positive act demonstrating competence. Noncompliance has too many legitimate explanations, patient-specific factors, resource constraints, evolving science, clinical judgment, to function as standalone proof of negligence. The universe of reasons a physician might appropriately deviate from a guideline is vast. The universe of reasons a physician might appropriately follow one is straightforward.

SPEAKER_02 8:51

And honestly, from the clinical side, that logic tracks. I deviate from guidelines constantly, not because I am being negligent, but because the patient in front of me does not fit the guideline population. A guideline that says anticoagulate all PE patients does not account for the patient who is actively hemorrhaging. A guideline that says admit all troponin-positive chest pain does not account for the demand ischemia troponin leak in a septic patient where the primary treatment is antibiotics, not a cardiac catheterization lab. The fact that I did not follow a guideline standing alone should not be enough to establish breach. I agree with that.

SPEAKER_00 9:30

Whether you find the asymmetry fair or not, the practical question for physicians is the same. How do you use this?

SPEAKER_03 9:38

The restatement did not just change the definition of reasonable care. Combined with existing procedural mechanisms, Section 6B creates three distinct defense pipelines. Strategic pathways that convert bedside documentation into courtroom advantage. Sarah, take us through them.

SPEAKER_00 10:00

Pipeline 1 is the early disposition pipeline. Here's the mechanism. If a physician's care demonstrably complied with an authoritative guideline and that compliance is documented in the medical record, defense counsel can move for summary judgment on the breach element of the malpractice claim. Under Section 6, B, guideline compliance constitutes prima facie evidence of non-breach. If the plaintiff cannot produce countervailing evidence sufficient to overcome that prima facie showing, the case can be resolved before trial.

SPEAKER_03 10:33

No trial.

SPEAKER_00 10:40

Exactly. Summary judgment eliminates the case entirely. For the physician, this is the cleanest possible outcome, but it requires three things from you. The guideline must be authoritative, issued by a recognized professional body with rigorous methodology. It must be applicable, relevant to the clinical scenario and the patient population. And it must be documented. The record must show that you knew the guideline, applied it, and that your care aligned with its recommendations.

SPEAKER_02 11:08

Let me be concrete about what that documentation looks like. Go back to our chest pain patient. Here is what I would chart: risk stratification performed using heart pathway protocol. Heart score three, low risk, high sensitivity troponin negative times two at zero hours and three hours. Per heart pathway evidence, Bacchus and Colleagues, Annals of Emergency Medicine 2013, updated validation in JAMA cardiology 2024, 30-day MACE risk less than 1% in this cohort. Clinical decision discharge with next day cardiology, follow-up and return precautions. Decision discussed with patient who verbalized understanding of risk-benefit assessment and return criteria. That note names the guideline, it cites the evidence, it connects the evidence to this patient, it documents the clinical decision, and it documents the conversation with the patient. That is the entry ticket to pipeline one.

SPEAKER_03 12:08

What is the vulnerability in this pipeline?

SPEAKER_00 12:11

Plaintiffs will attack the applicability prong. Was this guideline designed for this patient population? Did comorbidities take the patient outside the guideline's scope? Was the guideline current at the time of treatment? The more your documentation addresses patient-specific applicability, the harder that attack becomes. Under Dober versus Merrill Dow Pharmaceuticals and its state law equivalents, trial judges serve as gatekeepers for expert testimony. If a plaintiff's expert offers an opinion on the standard of care that directly contradicts an authoritative clinical practice guideline without providing a scientifically rigorous basis for the departure, defense counsel can move to exclude that expert's testimony. In most malpractice cases, the plaintiff's case rises or falls with their expert. Exclude the expert, and the plaintiff often cannot establish the standard of care or breach, the case collapses.

SPEAKER_02 13:13

This is the pipeline that should make every hospitalist pay attention. Because what it means is this when your chart reflects the same evidentiary foundation that authoritative guidelines rely on, when your documentation shows that you were thinking about the evidence, applying it to this patient and making reasoned decisions, it becomes very hard for a plaintiff's expert to credibly argue that your care was incompetent. And it becomes much easier for a judge to look at that expert's contrary opinion and say, this opinion lacks sufficient scientific basis. It is excluded.

SPEAKER_03 13:47

What is the vulnerability here?

SPEAKER_00 13:50

This pipeline depends heavily on the jurisdiction's gatekeeping standard. Federal courts and states that follow Dobert provide the strongest framework. States that still use the older Fry general acceptance standard may be less receptive to guideline-based expert exclusion arguments. You need to know what standard applies in your state. Section 8 of the restatement endorses the lost chance doctrine with proportional damages. If a breach is established, damages are calculated proportionally based on the quantum of chance, the negligence destroyed, not the full injury value. Here is why this matters for defense. Thorough documentation of a patient's pre-existing risk factors, baseline prognosis, and comorbidity burden directly reduces the proportional damages calculation. If the record establishes that the patient had a 30% pre-existing mortality risk from their underlying condition, the negligence attributable damages are calculated against only the lost increment of chance, not the full outcome.

SPEAKER_02 15:05

This is where severity scores and comorbidity documentation become legal tools, not just clinical tools. Think about an ICU admission. I document an Apache II score of 24 on admission. That corresponds to approximately 40% predicted ICU mortality. I document the significant comorbidities, end-stage renal disease on hemodialysis, NYHA, class III heart failure with an ejection fraction of 25%, poorly controlled diabetes with a hemoglobin A, 1C of 10.2. Every one of those documented risk factors reduces the denominator in any future proportional damages calculation. The patient was already critically ill. The baseline risk was already high. If something goes wrong and breaches established, the damages should reflect only what my care changed, not the entire outcome.

SPEAKER_00 16:01

An important caveat, the lost chance doctrine, is not universally adopted. Alabama, for example, explicitly rejects it. McAfee v. Baptist Medical Center in 1994 established that plaintiffs must prove negligence probably caused the injury. Greater than 50% likelihood. The proportional recovery framework of Section 8 has no current foothold in Alabama law. Interestingly, in states that reject lost chance, the traditional all-or-nothing causation framework may actually benefit defendants when baseline risk is high, because the plaintiff cannot meet the greater than 50% causation threshold. So the value of pipeline three is jurisdiction dependent.

SPEAKER_03 16:46

Three pipelines, three different strategic outcomes, but all three run on the same fuel.

SPEAKER_02 16:53

Documentation.

SPEAKER_03 17:03

Michael, you hinted at it earlier.

SPEAKER_02 17:06

Clinical practice guidelines are population-level tools. They aggregate evidence across thousands of patients to produce generalized recommendations, but the patient in front of me at 2 a.m. is not an aggregate. They have specific anatomy, specific comorbidities, specific social determinants, specific medication interactions, specific values about what risks they are willing to accept.

SPEAKER_00 17:31

Plaintiffs will exploit this gap. The argument goes: your guideline was not written for this patient. This patient's specific factor, their renal function, their medication profile, their age, their comorbidities, took them outside the guidelines intended population. Following the guideline in this context was not competent. It was lazy.

SPEAKER_03 17:53

This has been called the snowflake effect. The inherent tension between the population-level evidence and individual clinical decision-making. It is the oldest critique of evidence-based medicine, and it translates directly into a courtroom attack on guideline-based defense.

SPEAKER_02 18:12

And it is a legitimate critique. The 85-year-old on dialysis with a new pulmonary embolism. The anticoagulation guidelines were not validated in that population. The 22-year-old pregnant patient with sepsis. The surviving sepsis campaign bundles were not designed for pregnancy physiology. If I just blindly follow the guideline in those cases without thinking about whether it actually applies to this patient, that is not evidence-based medicine. That is cookbook medicine. And a good plaintiff's attorney will make that distinction very clearly for the jury.

SPEAKER_00 18:52

The counter to the snowflake effect is the same answer as everything else in this framework. Documentation. Specifically, documentation that demonstrates you did not blindly follow a guideline, you assessed its applicability to this patient, considered the patient-specific factors that might modify the recommendation, and made a reasoned clinical judgment. The guideline compliant physician who documents patient-specific reasoning is shielded. The guideline compliant physician who documents nothing beyond the order is exposed.

SPEAKER_02 19:27

Think of it this way: the guideline gets you in the door, the patient-specific reasoning locks the door behind you.

SPEAKER_03 19:35

For physicians practicing in Alabama, and Michael, this is your home turf. The restatements provisions collide head-on with existing law.

SPEAKER_02 19:55

It defines the standard of care as the level of care exercised by similarly situated physicians in the same general neighborhood. That is the old framework, the one the restatement is designed to replace.

SPEAKER_00 20:08

And Alabama courts have repeatedly reinforced that standard. Ex parte, Stephen M. Taylor, MD in 2025 reinforced the AMLA's rigid procedural framework for expert qualification and pleading requirements. Hickson vs. Premier Medical Group in 2025 continued the same trend. Alabama's procedural strictures make it harder for plaintiffs to bring cases, but they also lock in the customary standard in ways that resist the restatement's competence-based approach. Correct. McAfee v. Baptist Medical Center in 1994 established the rule. Plaintiffs must prove negligence probably caused the injury. Greater than 50% likelihood.

SPEAKER_02 21:08

And here is the thing: Alabama is not alone in this posture. When the ALI published its restatement of the law, liability insurance a few years ago, several states, Arkansas, Michigan, North Dakota, Ohio, preemptively enacted legislation forbidding their courts from relying on it before it was even finalized. That set a precedent. A similar effort targeting the medical malpractice restatement is plausible. The Alabama Defense Lawyers Association actively monitors ALI initiatives. Organized resistance is real.

SPEAKER_03 21:42

So is the Section 6B strategy useless in Alabama?

SPEAKER_00 21:46

No. And this is the critical insight. Even within the AMLA's framework, demonstrating guideline compliance is also evidence of meeting the customary standard. As evidence based Practice becomes the national norm. The physician who follows recognized guidelines is simultaneously satisfying Alabama's same general neighborhood test and building a section six B record for any future in which Alabama courts or the legislature adopt the restatements approach.

SPEAKER_02 22:19

That is the practical takeaway for Alabama hospitalists and really for any physician in a resistant state. Build the record as if the restatement were already law, it cost you nothing. You are documenting guideline compliance and clinical reasoning within the existing framework. You are building a defense that works under the AMLA today and under the restatement tomorrow. You are not choosing between two systems.

SPEAKER_03 22:46

You are building a chart that survives about There is one more implication of Section 6 that deserves attention. And it may be the most surprising.

SPEAKER_02 23:02

For decades, defensive medicine has been the elephant in the room. We order tests we know are unnecessary. We admit patients who do not need to be admitted. We consult a specialist for problems we can manage ourselves, and we do it because we are afraid of getting sued. The standard thinking has always been more is safer. More tests, more admissions, more consultations, more documentation of everything you possibly considered. But section six B inverts that logic. If following an evidence-based guideline and documenting it is a stronger legal defense than ordering every test, then the restatement may actually liberate physicians to practice evidence-based medicine without the fear of litigation hanging over every decision.

SPEAKER_00 23:49

It is a genuine paradox. A legal provision designed to strengthen the defense may simultaneously reduce defensive medicine because the strongest defense is no longer I did everything, but rather I did what the evidence supported and I documented why.

SPEAKER_02 24:08

Under the old framework, the defensive play was to admit, observe, get serial troponins, maybe stress test, maybe a CT angiogram to cover every possible base. Under section six B, the defensive play is to follow the heart pathway, document it and discharge the patient. The evidence-based decision becomes the legally defensible decision. That is a fundamental shift. It aligns what is best for the patient with what is best for your legal protection. And that almost never happens in malpractice law.

SPEAKER_03 24:41

The Choosing Wisely campaign has been pushing this message from the clinical side for years. Stop ordering unnecessary tests. Section 6B may be the first legal mechanism that supports the same message from the courtroom's side. All three defense pipelines converge on a single operational principle. Michael? What is it?

SPEAKER_02 25:06

The chart is your entry ticket. None of these strategies work without contemporaneous documentation that connects your clinical decisions to the evidence base. Here's what that looks like in practice. Four things you can start doing tonight. Number one, name the guideline. When your care aligns with a recognized clinical practice guideline, say so in the chart. Do not assume someone will figure it out later. Do not assume your order for an ox appearance speaks for itself. State the guideline, name the source connect it to the patient. Number two, document the patient's specific fit. When you follow a guideline, note why it applies to this patient. When you deviate, note why it does not. This is the snowflake defense. You are showing that you thought about whether the population level evidence fits this individual patient. Here is an example. Say you have a patient with an acute pulmonary embolism, but they are also actively bleeding from a GI source. The ACCP guidelines recommend therapeutic anticoagulation with inoxoperin or a direct oral anticoagulant for acute PE. But you cannot anticoagulate a patient who is hemorrhaging, so you document ACCP guidelines recommend therapeutic anticoagulation for acute PE. A guideline not followed in this case due to active GI hemorrhage, hemoglobin drop from 12.1 to 8.3 over 24 hours, Melina on exam. Alternative approach an IVC filter placement with a plan to initiate anticoagulation once hemostase is achieved. This decision reflects a patient-specific risk-benefit assessment discussed with interventional radiology and GI patient counseled on rationale. That note is not long, but it does everything. It names the guideline, it explains the deviation, it documents the patient's specific reasoning, it shows collaboration, and it shows the patient was informed. Number three, quantify baseline risk. In critically ill patients document the pre-existing risk profile, severity scores, comorbidity indices, prognosis discussions, Ipach 2, Charleston Comorbidity Index, Baseline Ejection Fraction, Hemoglobin A1C. These are not just clinical tools. In any jurisdiction that adopts lost chance with proportional damages, they become the denominator in the damages calculation. Number four, build the record prospectively. Do not wait for a bad outcome. Build the guideline compliance record on every patient. Because the case that generates a claim is indistinguishable from the case that does not at the time of treatment. The physician who documents clinical reasoning on every admission has a chart that survives scrutiny. The physician who only documents carefully after an adverse event has a chart that invites it.

SPEAKER_00 28:04

And I want to emphasize something from the legal side. These documentation practices are not burdensome add-ons to your clinical workflow. They are the clinical reasoning you are already doing. Written down, the physician who is thinking about whether the guideline fits this patient is already doing good medicine. Writing it in the chart is not extra work. It is making your good medicine visible.

SPEAKER_02 28:29

Exactly. The restatement is not asking you to practice differently. It is asking you to prove that you practice the way you should have. Show your work.

SPEAKER_03 28:38

Let us close with a rapid takeaways. Section 6b creates an asymmetrical shield. Defendants can use clinical practice guideline compliance as prima facie evidence of non-breach. Plaintiffs cannot use non-compliance the same way. This is the most strategically significant provision in the 2024 restatement for practicing physicians. Three defense pipelines emerge. First, guideline compliance to summary judgment, early case dismissal. Second, guideline alignment to expert exclusion under Dober. Collapse of the plaintiff's case. Third, documented baseline risk to proportional damages reduction under lost chance. Limit your exposure. All three require the same fuel. Documentation. The snowflake effect is the counter move. Plaintiffs will argue the guideline was not designed for this patient. Your documentation of patient-specific applicability neutralizes this attack. Alabama's AMLA collides with the restatement. The customary standard, lost chance rejection, and procedural strictures create maximum friction. But guideline-based documentation works within the existing framework and positions you for any future shift. The chart is not just your defense. It is your entry ticket to the defense pipeline. Without contemporaneous documentation of guideline compliance and clinical reasoning, none of these strategies are available. Build the record on every patient. The case that becomes a lawsuit is indistinguishable from the one that does not at the time of treatment. And guideline compliance may reduce defensive medicine. If following the evidence and documenting it is a stronger defense than ordering every test, the restatement may paradoxically liberate an evidence-based practice from the fear of litigation.

SPEAKER_02 30:52

That is what Section 6B offers. Not a guarantee, not an automatic win, but a strategic architecture, a way to convert the evidence-based medicine you are already practicing into a courtroom defense that works. The chart is the entry ticket.

SPEAKER_03 31:10

This has been the Charted Defense. Thank you for listening. If you found this episode valuable, share it with a colleague who needs to hear it. We will be back next week. This podcast is for educational purposes only and does not constitute legal advice or medical advice. The legal principles discussed may vary significantly by jurisdiction. The strategic defense applications described are analytical constructs based on the REST statements provisions. They have not been tested in court as of the date of publication. Case details and legal analysis are drawn from publicly available court records, published legal scholarship, ALI publications, and regulatory documents. Laws governing medical malpractice vary by state. Consult a licensed attorney in your jurisdiction for legal guidance specific to your situation.